Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Letters

Overdose advice

David W. Johnson
CMAJ April 15, 2003 168 (8) 957-958;
David W. Johnson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

I read with interest the findings of the study published recently in CMAJ1 examining the quality of poison management information in the 2001 edition of the Compendium of Pharmaceuticals and Specialties (CPS).2 As a member of the CPS editorial advisory panel, I am familiar with the process by which the content of product monographs is determined. This is pertinent to understanding the appropriate use of the information contained in those monographs.

The product monographs, which are printed in the white section of CPS, are created by drug manufacturers and approved by Health Canada, and the Canadian Pharmacists Association (CPhA) has no authority to change or update their content. It is incumbent on pharmaceutical manufacturers to update their own monographs and to apply for approval of the changes; alternatively, such changes can be requested by Health Canada.

As mentioned by the authors,1 one step that the CPhA has taken to augment this resource is to provide its own evidence-based drug monographs, written by staff pharmacists and reviewed by a panel of expert Canadian physicians and pharmacists. Some of these cover single drugs, whereas others cover drug classes. These more general monographs are printed on grey pages to differentiate them from the manufacturers' product monographs. The content of the CPhA-generated monographs, including the overdose treatment section, is owned by CPhA and is regularly reviewed and updated. Contact information for poison control centres is also listed in the CPS (in the yellow pages).

CPhA recognizes that product monographs may not be the best source of poison management information. Therefore, CPhA is working with the Canadian Association of Poison Control Centres to explore other ways of improving the quality of advice about overdoses contained within CPS. In the interim, however, physicians treating patients with a suspected drug overdose, especially for a drug with which they are unfamiliar, should contact the local poison centre to ensure that the care they are initiating is optimal.

David W. Johnson Associate Professor Departments of Pediatrics and of Pharmacology and Therapeutics Calgary, Alta.

References

  1. 1.↵
    Brubacher JR, Purssell R, Kent DA. Salty broth for salicylate poisoning? Adequacy of overdose management advice in the 2001 Compendium of Pharmaceuticals and Specialties. CMAJ 2002; 167 (9): 992-6.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    Canadian Pharmacists Association. Compendium of pharmaceuticals and specialties. 36th ed. Ottawa: The Association; 2001.
PreviousNext
Back to top

In this issue

CMAJ
Vol. 168, Issue 8
15 Apr 2003
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Overdose advice
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Overdose advice
David W. Johnson
CMAJ Apr 2003, 168 (8) 957-958;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Overdose advice
David W. Johnson
CMAJ Apr 2003, 168 (8) 957-958;
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • References
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Responding to Bill C-7
  • Benefits of nirmatrelvir–ritonavir remain unproven for some populations
  • Renalism
Show more Letters

Similar Articles

Collections

  • Topics
    • Drugs: adverse reactions
    • Emergency medicine
    • Pharmacology & toxicology

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2022, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire